Clinical trials: Platelet Refractoriness, open to volunteers
Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet…
- Trial name
- NCT07072247
- Testing
- CD19 and BCMA-targeted allogeneic CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hematological Malignancies, Platelet Transfusion Refractoriness (PTR)
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
Platelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of…
- Conditions
- Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies
- Trial name
- AB-HLA-2026 (NCT07635511)
- Testing
- Acalabrutinib maleate, bortezomib, HLA-matched or crossmatched irradiated platelets
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Platelet Transfusion Refractoriness
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
This is a randomized, open-label, phase IB/II clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.
- Trial name
- NCT06792019
- Testing
- CM313(SC) injection-low dose, CM313(SC) injection-high dose
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Keymed Biosciences Co.Ltd
Severe Aplastic Anemia, Platelet Transfusion Refractoriness
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR).
- Trial name
- NCT06254560
- Testing
- Rituximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China